A Phase 3 interventional study of Secukinumab and Placebo in Non-radiographic Axial Spondyloarthritis, sponsored by Novartis Pharmaceuticals. Completed at 29 sites in China. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-04-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China — 6 open to participants now, 6 under way, 3 of them phase 3. Non-Radiographic Axial Spondyloarthritis · China.
Among the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China, this one is the 8th largest by enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2021, is one of 6 in phase 3, and was the 3rd registered.
33 studies on the registry are indexed under Non-Radiographic Axial Spondyloarthritis; 12 are open to participants now.
Browse Non-Radiographic Axial Spondyloarthritis studies →6 of the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China are open now. Recruiting first, the newest first:
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Sites in China
Ages 18+
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18+
Chinese PLA General Hospital · Sites in China
Ages 18–65
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Sites in China
Ages 18+
Lingli Dong · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 5 Non-Radiographic Axial Spondyloarthritis studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 7 · Phase 4 1
First in 2019; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 137 is below the median of 225 across 20 interventional studies indexed under Non-Radiographic Axial Spondyloarthritis.
Median enrollment 227 across the 10 interventional studies, 10,000 across the 1 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 9 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Non-Radiographic Axial Spondyloarthritis — fewer than ten, so there is no comparison to draw.
1 of the studies in Non-Radiographic Axial Spondyloarthritis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07339566Phase 3Lingli DongEfficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Non-Radiographic Axial Spondyloarthritis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the efficacy, safety, and tolerability of secukinumab in Chinese patients with active non-radiographic axial spondyloarthritis (nr-axSpA).
This was a randomized, double-blind, placebo-controlled study. Approximately 134 participants were planned to be randomized in a 1:1 ratio to receive secukinumab 150 mg subcutaneously (s.c.) or placebo.
The double-blind treatment period lasted for 16 weeks. At the end of this period, all participants, including those who initially received placebo, switched to open-label treatment with secukinumab 150 mg s.c.
The first dose of open-label treatment was administered at the Week 16 visit, after completing all necessary assessments for that visit. However, the participants and investigators remained blinded to the original treatment assignment. At Week 24, participants who did not respond to the treatment (defined as not achieving Ankylosing SpondyloArthritis International Society 20 [ASAS20] response) were given a higher dose of secukinumab (300 mg s.c.), while responders continued with the 150 mg s.c. dose. The study treatment continued until Week 48. Four weeks after the last study treatment administration, an end-of-treatment visit was conducted at Week 52.
Additionally, a post-treatment safety follow-up visit was performed 12 weeks after the last study treatment administration for all participants, whether they completed the entire study as planned or exited early.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Participants received secukinumab 150 mg in a pre-filled syringe (PFS). Treatment was double-blinded until Week 12. From Week 16, participants continued with an open-label treatment of secukinumab 150 mg. At Week 24, non-responders (not achieving ASAS20) were escalated to secukinumab 300 mg, while responders continued with secukinumab 150 mg.
Drug: Secukinumab
Participants initially received a placebo in a pre-filled syringe (PFS) in a double-blinded manner until Week 12. At Week 16, they switched to an open-label treatment of secukinumab 150 mg. At Week 24, non-responders (not achieving ASAS20) were escalated to secukinumab 300 mg, while responders continued with secukinumab 150 mg.
Drug: Placebo
Secukinumab 150 mg s.c. using a PFS at Baseline, Weeks 1, 2, and 3, followed by administration every 4 weeks from Week 4 until Week 12. At Week 16, all participants continued or switched to receiving secukinumab 150 mg s.c. every 4 weeks, using a PFS. This treatment regimen continued from Week 16 through Week 48. For participants who did not respond to the secukinumab 150 mg dose during the open-label period, the dose was increased to 300 mg s.c., using two PFS, also administered every 4 weeks.
Also known as: AIN457
Placebo s.c. using a PFS at baseline, Weeks 1, 2 and 3, followed by administration every 4 weeks from Week 4 until Week 12.
Assessment of SpondyloArthritis International Society 40 (ASAS40) Response Rate in TNF-alpha-inhibitor-naive Participants at Week 16
ASAS40 response was defined as relative improvement of at least 40% and absolute improvement of at least 2 units on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening at all in the remaining domain. The 4 main domains of the ASAS are: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of TNF-alpha-inhibitor-naïve participants who achieved ASAS40 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders
Time frame: Baseline, Week 16
ASAS40 Response Rate in All Participants at Week 16
ASAS40 response was defined as relative improvement of at least 40% and absolute improvement of at least 2 units on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening at all in the remaining domain. The 4 main domains of the ASAS are: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of participants who achieved ASAS40 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders
Time frame: Baseline, Week 16
ASAS 5/6 Response Rate at Week 16.
The ASAS 5/6 response was defined as an improvement of ≥20% in at least five of all six domains of the ASAS: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]); 5) spinal mobility represented by the BAS Disease Metrology Index (BASDMI) (scale ranged from 0 \[no limitation of movement\] to 10 \[very severe limitation of movement\]; and 6) C-reactive protein (acute phase reactant). The percentage of participants who achieved ASAS 5/6 response at Week 16 was assessed using a logistic regression model. Missing responses were imputed as non-responders. Discontinued participants were considered non-responders
Time frame: Baseline, Week 16
Change From Baseline in Total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 16
The BASDAI consisted of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which was used to answer 6 questions pertaining to the 5 major symptoms of AS: 1. Fatigue; 2. Spinal pain; 3. Joint pain / swelling; 4. Areas of localized tenderness (called enthesitis, or inflammation of tendons and ligaments); 5. Morning stiffness duration; 6. Morning stiffness severity. BASDAI score was calculated as the mean of the questions 5 and 6. The resulting 0 to 10 score was added to the scores from questions 1-4. The resulting 0 to 50 score was divided by 5 to give a final 0-10 BASDAI score, where higher score indicated high disease activity. The change from baseline in BASDAI scores at Week 16 was assessed using Mixed-effects model repeated measures (MMRM). A negative change from baseline indicated improvement.
Time frame: Baseline, Week 16
BASDAI 50 Rate at Week 16
The BASDAI consisted of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which was used to answer 6 questions pertaining to the 5 major symptoms of AS: 1. Fatigue; 2. Spinal pain; 3. Joint pain / swelling; 4. Areas of localized tenderness (called enthesitis, or inflammation of tendons and ligaments); 5. Morning stiffness duration; 6. Morning stiffness severity. BASDAI score was calculated as the mean of the questions 5 and 6. The resulting 0 to 10 score was added to the scores from questions 1-4. The resulting 0 to 50 score was divided by 5 to give a final 0-10 BASDAI score, where higher score indicated high disease activity. BASDAI 50 was defined as an improvement of at least 50% in the BASDAI total score compared to baseline. The percentage of participants achieving BASDAI 50 at Week 16 was assessed using a logistic regression model. Discontinued participants and with missing responses were considered non-responders
Time frame: Baseline, Week 16
Change From Baseline of High Sensitivity C-Reactive Protein (hsCRP) at Week 16
hsCRP was measured as a marker of inflammation from blood samples. The change from baseline in hsCRP at Week 16 was assessed using MMRM. It was expressed as a ratio of Week 16 to baseline values. Ratios less than 1.0 at Week 16 represented reduced hsCRP.
Time frame: Baseline, Week 16
Change From Baseline in Total Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16
The BASFI is a set of 10 questions designed to determine the degree of functional limitation in subjects with AS. The questions were chosen on the basis of predominant input from subjects with AS. The first eight questions consider activities related to functional anatomy. The final two questions assess the subjects' ability to cope with everyday life. A 0-10 scale (captured as a continuous VAS) is used to answer the questions. The BASFI score is the mean of the ten scales - a value between 0 and 10, with higher scores indicating a higher degree of functional limitation in patients. The change from baseline in BASFI at Week 16 was assessed. A negative change from baseline indicated improvement.
Time frame: Baseline, Week 16
Change From Baseline in Sacroiliac Joint (SIJ) Edema Score on Magentic Resonance Imaging (MRI) at Week 16
The MRI assessment of the total edema score of the Sacroiliac Joint (SIJ) measured the degree of edema or fluid accumulation in the joint. The score ranged from 0 to 24, with higher scores indicating more severe inflammation. The change from baseline in inflammation, as measured by the SI joint total edema score at Week 16, was evaluated using an ANCOVA model. Any missing data was imputed using multiple imputation prior to running the ANCOVA analysis.
Time frame: Baseline, Week 16
ASAS20 Response Rate at Week 16
ASAS20 response was defined as relative improvement of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening of ≥20% and ≥1 unit at all in the remaining domain. The 4 main domains of ASAS are 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]) The percentage of participants who achieved ASAS20 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders
Time frame: Baseline, Week 16
Change From Baseline in Short Form-36 Physical Component Summary (SF-36 PCS) at Week 16
SF-36 was an instrument used to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consisted of eight subscales (domains) that could be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. Each domain score ranged from 0 to 100, with higher scores indicating a higher level of functioning. The Physical Component Summary (PCS) was an overall summary score calculated from the 8 domains. It was a norm-based score with a mean of 50 and a standard deviation of 10. Higher scores indicated a higher level of functioning. The change from baseline in PCS at Week 16 was evaluated using MMRM. A positive change from baseline indicated an improvement.
Time frame: Baseline, Week 16
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16
The ASQoL was a self-administered questionnaire designed to assess health-related quality of life (HRQoL) in participants with ankylosing spondylitis. The ASQoL contained 18 items with a dichotomous yes/no response option. A single point was assigned for each "yes" response and no points for each "no" response resulting in overall scores that ranged from 0 (least severity) to 18 (highest severity). As such, a lower score indicated a better quality of life. Items included an assessment of mobility/energy, self-care, and mood/emotion. The change from baseline in ASQoL at Week 16 was assessed using MMRM. A negative change from baseline indicated an improvement.
Time frame: Baseline, Week 16
ASAS Partial Remission Rate at Week 16
The ASAS partial remission criteria were defined as a value not above 2 units (on a scale of 10) in each of the 4 main ASAS domains: 1. Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2. Back Pain (assessed on a scale of 0 \[no pain\] to 10 \[severe pain\]); 3. Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4. Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of participants who achieved ASAS partial remission response at Week 16 was assessed using a logistic regression model. Missing responses were imputed as non-responders. Discontinued participants were considered non-responders.
Time frame: Baseline, Week 16
| Milestone | Secukinumab | Placebo |
|---|---|---|
| Started | 68 | 69 |
| Completed | 67 | 68 |
| Not completed | 1 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Subject decision | 0 | 1 |
| Milestone | Secukinumab | Placebo |
|---|---|---|
| Started | 67 | 68 |
| Escalated to secukinumab 300 mg | 12 | 17 |
| Completed | 64 | 65 |
| Not completed | 3 | 3 |
| Withdrew: Subject discontinuation | 3 | 3 |
ASAS40 response was defined as relative improvement of at least 40% and absolute improvement of at least 2 units on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening at all in the remaining domain. The 4 main domains of the ASAS are: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (Bath Ankylosing Spondylitis Functional Index \[BASFI\]) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of TNF-alpha-inhibitor-naïve participants who achieved ASAS40 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders
| Percentage of participants | Secukinumab | Placebo |
|---|---|---|
| Assessment of SpondyloArthritis International Society 40 (ASAS40) Response Rate in TNF-alpha-inhibitor-naive Participants at Week 16 | 58.72 (46.41 to 71.03) | 26.03 (15.12 to 36.94) |
ASAS40 response was defined as relative improvement of at least 40% and absolute improvement of at least 2 units on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening at all in the remaining domain. The 4 main domains of the ASAS are: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of participants who achieved ASAS40 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders
| Percentage of participants | Secukinumab | Placebo |
|---|---|---|
| ASAS40 Response Rate in All Participants at Week 16 | 60.10 (48.46 to 71.75) | 24.78 (14.57 to 34.98) |
The ASAS 5/6 response was defined as an improvement of ≥20% in at least five of all six domains of the ASAS: 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]); 5) spinal mobility represented by the BAS Disease Metrology Index (BASDMI) (scale ranged from 0 \[no limitation of movement\] to 10 \[very severe limitation of movement\]; and 6) C-reactive protein (acute phase reactant). The percentage of participants who achieved ASAS 5/6 response at Week 16 was assessed using a logistic regression model. Missing responses were imputed as non-responders. Discontinued participants were considered non-responders
| Percentage of participants | Secukinumab | Placebo |
|---|---|---|
| ASAS 5/6 Response Rate at Week 16. | 61.97 (51.12 to 72.82) | 25.89 (16.13 to 35.64) |
The BASDAI consisted of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which was used to answer 6 questions pertaining to the 5 major symptoms of AS: 1. Fatigue; 2. Spinal pain; 3. Joint pain / swelling; 4. Areas of localized tenderness (called enthesitis, or inflammation of tendons and ligaments); 5. Morning stiffness duration; 6. Morning stiffness severity. BASDAI score was calculated as the mean of the questions 5 and 6. The resulting 0 to 10 score was added to the scores from questions 1-4. The resulting 0 to 50 score was divided by 5 to give a final 0-10 BASDAI score, where higher score indicated high disease activity. The change from baseline in BASDAI scores at Week 16 was assessed using Mixed-effects model repeated measures (MMRM). A negative change from baseline indicated improvement.
| Score on a scale | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline in Total Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score at Week 16 | -3.70 ± 0.240 | -2.15 ± 0.237 |
The BASDAI consisted of a 0 through 10 scale (0 being no problem and 10 being the worst problem, captured as a continuous VAS), which was used to answer 6 questions pertaining to the 5 major symptoms of AS: 1. Fatigue; 2. Spinal pain; 3. Joint pain / swelling; 4. Areas of localized tenderness (called enthesitis, or inflammation of tendons and ligaments); 5. Morning stiffness duration; 6. Morning stiffness severity. BASDAI score was calculated as the mean of the questions 5 and 6. The resulting 0 to 10 score was added to the scores from questions 1-4. The resulting 0 to 50 score was divided by 5 to give a final 0-10 BASDAI score, where higher score indicated high disease activity. BASDAI 50 was defined as an improvement of at least 50% in the BASDAI total score compared to baseline. The percentage of participants achieving BASDAI 50 at Week 16 was assessed using a logistic regression model. Discontinued participants and with missing responses were considered non-responders
| Percentage of participants | Secukinumab | Placebo |
|---|---|---|
| BASDAI 50 Rate at Week 16 | 64.04 (52.82 to 75.27) | 25.77 (15.68 to 35.85) |
hsCRP was measured as a marker of inflammation from blood samples. The change from baseline in hsCRP at Week 16 was assessed using MMRM. It was expressed as a ratio of Week 16 to baseline values. Ratios less than 1.0 at Week 16 represented reduced hsCRP.
| Ratio: Week 16 / Baseline | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline of High Sensitivity C-Reactive Protein (hsCRP) at Week 16 | 0.38 ± 1.137 | 0.74 ± 1.136 |
The BASFI is a set of 10 questions designed to determine the degree of functional limitation in subjects with AS. The questions were chosen on the basis of predominant input from subjects with AS. The first eight questions consider activities related to functional anatomy. The final two questions assess the subjects' ability to cope with everyday life. A 0-10 scale (captured as a continuous VAS) is used to answer the questions. The BASFI score is the mean of the ten scales - a value between 0 and 10, with higher scores indicating a higher degree of functional limitation in patients. The change from baseline in BASFI at Week 16 was assessed. A negative change from baseline indicated improvement.
| Score on a Scale | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline in Total Bath Ankylosing Spondylitis Functional Index (BASFI) at Week 16 | -2.04 ± 0.225 | -0.93 ± 0.222 |
The MRI assessment of the total edema score of the Sacroiliac Joint (SIJ) measured the degree of edema or fluid accumulation in the joint. The score ranged from 0 to 24, with higher scores indicating more severe inflammation. The change from baseline in inflammation, as measured by the SI joint total edema score at Week 16, was evaluated using an ANCOVA model. Any missing data was imputed using multiple imputation prior to running the ANCOVA analysis.
| Score on a Scale | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline in Sacroiliac Joint (SIJ) Edema Score on Magentic Resonance Imaging (MRI) at Week 16 | -3.09 ± 0.34 | -0.84 ± 0.35 |
ASAS20 response was defined as relative improvement of at least 20% and absolute improvement of at least 1 unit on a 0 to 10 scale in at least 3 of the 4 main domains of the ASAS and no worsening of ≥20% and ≥1 unit at all in the remaining domain. The 4 main domains of ASAS are 1.Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2.Back Pain (score ranged from 0 \[no pain\] to 10 \[severe pain\]); 3.Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4.Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]) The percentage of participants who achieved ASAS20 response at Week 16 was assessed using a logistic regression model. Discontinued participants and those with missing responses were considered non-responders
| Percentage of participants | Secukinumab | Placebo |
|---|---|---|
| ASAS20 Response Rate at Week 16 | 78.10 (68.29 to 87.91) | 47.60 (35.82 to 59.39) |
SF-36 was an instrument used to measure health-related quality of life among healthy patients and patients with acute and chronic conditions. It consisted of eight subscales (domains) that could be scored individually: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role- Emotional, and Mental Health. Each domain score ranged from 0 to 100, with higher scores indicating a higher level of functioning. The Physical Component Summary (PCS) was an overall summary score calculated from the 8 domains. It was a norm-based score with a mean of 50 and a standard deviation of 10. Higher scores indicated a higher level of functioning. The change from baseline in PCS at Week 16 was evaluated using MMRM. A positive change from baseline indicated an improvement.
| Score on a Scale | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline in Short Form-36 Physical Component Summary (SF-36 PCS) at Week 16 | 9.35 ± 0.772 | 4.34 ± 0.753 |
The ASQoL was a self-administered questionnaire designed to assess health-related quality of life (HRQoL) in participants with ankylosing spondylitis. The ASQoL contained 18 items with a dichotomous yes/no response option. A single point was assigned for each "yes" response and no points for each "no" response resulting in overall scores that ranged from 0 (least severity) to 18 (highest severity). As such, a lower score indicated a better quality of life. Items included an assessment of mobility/energy, self-care, and mood/emotion. The change from baseline in ASQoL at Week 16 was assessed using MMRM. A negative change from baseline indicated an improvement.
| Score on a scale | Secukinumab | Placebo |
|---|---|---|
| Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Scores at Week 16 | -4.90 ± 0.455 | -3.07 ± 0.447 |
The ASAS partial remission criteria were defined as a value not above 2 units (on a scale of 10) in each of the 4 main ASAS domains: 1. Patient's Global Assessment of Disease Activity (score ranged from 0 \[not active\] to 10 \[very active\]); 2. Back Pain (assessed on a scale of 0 \[no pain\] to 10 \[severe pain\]); 3. Function (BASFI) (score ranged from 0 \[easy\] to 10 \[impossible\]); 4. Inflammation (mean of BASDAI questions 5 and 6 concerning morning stiffness intensity and duration) (score ranged from 0 \[none\] to 10 \[very severe\]). The percentage of participants who achieved ASAS partial remission response at Week 16 was assessed using a logistic regression model. Missing responses were imputed as non-responders. Discontinued participants were considered non-responders.
| Percentage of participants | Secukinumab | Placebo |
|---|---|---|
| ASAS Partial Remission Rate at Week 16 | 30.83 (19.92 to 41.73) | 14.52 (6.23 to 22.80) |
Collected over From start of treatment to end of study, assessed up to approximately 65 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Secukinumab 150 mg | 0/135 (0%) | 4/135 (3%) | 103/135 (76.3%) |
| Secukinumab 300 mg | 0/29 (0%) | 2/29 (6.9%) | 22/29 (75.9%) |
| Any Secukinumab | 0/135 (0%) | 6/135 (4.4%) | 114/135 (84.4%) |
| Placebo | 0/69 (0%) | 1/69 (1.4%) | 52/69 (75.4%) |
| Event | Secukinumab 150 mg | Secukinumab 300 mg | Any Secukinumab | Placebo |
|---|---|---|---|---|
| ParonychiaInfections and infestations | 0/135 | 1/29 | 1/135 | 0/69 |
| TonsillitisInfections and infestations | 0/135 | 1/29 | 1/135 | 0/69 |
| Anal fistulaGastrointestinal disorders | 0/135 | 0/29 | 0/135 | 1/69 |
| Gastritis erosiveGastrointestinal disorders | 1/135 | 0/29 | 1/135 | 0/69 |
| Rib fractureInjury, poisoning and procedural complications | 1/135 | 0/29 | 1/135 | 0/69 |
| Neuroendocrine tumour of the rectumNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/135 | 0/29 | 1/135 | 0/69 |
| Plasma cell mastitisReproductive system and breast disorders | 1/135 | 0/29 | 1/135 | 0/69 |
| Event | Secukinumab 150 mg | Secukinumab 300 mg | Any Secukinumab | Placebo |
|---|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 43/135 | 7/29 | 49/135 | 22/69 |
| HyperuricaemiaMetabolism and nutrition disorders | 26/135 | 4/29 | 28/135 | 10/69 |
| COVID-19Infections and infestations | 23/135 | 4/29 | 27/135 | 7/69 |
| HyperlipidaemiaMetabolism and nutrition disorders | 23/135 | 0/29 | 23/135 | 10/69 |
| Back painMusculoskeletal and connective tissue disorders | 4/135 | 0/29 | 4/135 | 10/69 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/135 | 4/29 | 9/135 | 4/69 |
| Intervertebral disc protrusionMusculoskeletal and connective tissue disorders | 14/135 | 1/29 | 15/135 | 0/69 |
| Low density lipoprotein increasedInvestigations | 14/135 | 1/29 | 14/135 | 5/69 |
| PharyngitisInfections and infestations | 3/135 | 3/29 | 5/135 | 1/69 |
| Suspected COVID-19Infections and infestations | 11/135 | 1/29 | 12/135 | 2/69 |
| Age, Continuous(Years) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Mean | 29.4 ± 7.83 | 29.4 ± 7.44 | 29.4 ± 7.61 |
| Sex: Female, Male(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Female | 23 | 17 | 40 |
| Male | 45 | 52 | 97 |
| Race/Ethnicity, Customized(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| Asian | 68 | 69 | 137 |
| TNF-alpha inhibitors exposure(Participants) | Secukinumab | Placebo | Total |
|---|---|---|---|
| TNF alpha-inhibitor-naive | 61 | 62 | 123 |
| Prior exposure to a TNF-alpha inhibitor | 7 | 7 | 14 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing access to patient-level data and supporting clinical documents from eligible studies with qualified external researchers. Requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to protect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Jul 2021 to primary completion in Apr 2024, 32 months.
Results were first posted in Jan 2026, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Secukinumab
Non-Radiographic Axial Spondyloarthritis →